Zai Lab: to await results of Fortitude-102 prior to reg. filing

Zai Lab: to await results of Fortitude-102 prior to reg. filing

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative biopharmaceutical company based in China and the United States, has announced that it will await the results of its Fortitude-102 trial before submitting a regulatory filing. The company has scheduled key presentations at upcoming investor conferences in September 2025, providing an opportunity for investors to stay informed about Zai Lab's progress and future plans.

On Thursday, September 4, 2025, at 10:20 a.m. ET, members of Zai Lab's senior management team will present at the Cantor Global Healthcare Conference in New York, NY [1]. Additionally, on Tuesday, September 9, 2025, at 2:35 p.m. ET, Zai Lab will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference, also in New York, NY. Live webcasts and archived replays of these events will be available on Zai Lab's Investor Relations page at ir.zailaboratory.com/webcasts-presentations and will be accessible for up to 90 days following the events [1].

Zai Lab's focus is on discovering, developing, and commercializing innovative products that address significant unmet medical needs in the areas of oncology, immunology, neuroscience, and infectious disease. The company's decision to await the Fortitude-102 trial results before filing for regulatory approval reflects its commitment to rigorous scientific standards and patient safety.

For more information about Zai Lab and its upcoming events, please visit www.zailaboratory.com or follow them at www.X.com/ZaiLab_Global. Contact details for investor relations and media inquiries are also available on the company's website [1].

References:
[1] https://www.biospace.com/press-releases/zai-lab-announces-participation-in-investor-conferences-in-september-2025